Oncology leads the charge in pharma Q1 earnings
Q1 earnings from Bristol-Myers Squibb, Bayer, Johnson & Johnson, AbbVie and Novartis showed strong growth by oncology drugs.
Oncology
Specialty Summits | Cardinal Health
Maximize your engagement with specialty providers and gain valuable insights on their perspectives through Cardinal Health’s Specialty Summits.
Five things for pharma marketers to know: Friday, August 31, 2018
AstraZeneca’s lupus drug fails to meet goals; FDA expands investigation into heart drugs; Lilly names new head of Oncology.
A tale of two lung cancer immunotherapies: Merck’s Keytruda takes the reins
Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
Has DTC in the oncology space kept up with science?
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
As CAR-Ts go from candidates to brands, what’s the marketing strategy?
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Five things for pharma marketers to know: Tuesday, January 30, 2018
Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda’s Zika vaccine receives FDA fast-track status
Five things for pharma marketers to know: Tuesday, January 23, 2018
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Five things for pharma marketers to know: Monday, January 22, 2018
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
Five things for pharma marketers to know: Wednesday, January 17, 2018
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
